Study of Metallothionein Levels in the Serum of Patients with Malignant Tumour

Authors

  • Luděk Melich Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Magdaléna Fořtová Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Božena Hosnedlová BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czech Republic
  • Jakub Podhájský Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Ondřej Rychlý Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Julia Werle Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Kristýna Burešová Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Kateřina Dunovská Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Lenka Vysloužilová Department of Biomedical Engineering and Assistive Technology, Czech Institute of Informatics, Robotics and Cybernetics, Czech Technical University, Prague, Czech Republic
  • Eva Klapková Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Karel Kotaška Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Jana Čepová Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Blanka Jedličková Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • Olga Štěpánková Department of Biomedical Engineering and Assistive Technology, Czech Institute of Informatics, Robotics and Cybernetics, Czech Technical University, Prague, Czech Republic
  • Richard Průša Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
  • René Kizek Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic https://orcid.org/0000-0002-0467-6169

DOI:

https://doi.org/10.54779/chl20230573

Keywords:

metallomics, cancer of the liver, pancreas, gall bladder, diagnosis, prognostic marker, electrochemical analysis, Brdička's reaction

Abstract

Metallothionein (MT) is a low molecular weight intracellular protein, the primary function of which is to maintain the homeostasis of heavy metals in living organisms. Only a few research has been carried on the topic molecular mechanism of MT. Recent research points to its significant relationship to carcinogenesis, spontaneous mutagenesis, and the effectiveness of antitumor drugs. Increased level of MT is studied as a potential indicator of increased metabolic activity in cancer. Electrochemical methods are a suitable analytical tool for MT detection. Temperature-denatured blood serum samples of patients diagnosed with cancer were studied using electrochemical analysis (Brdička's reaction). The obtained voltammograms were evaluated as the area under the curve (AUC response). To compare normal and abnormal MT levels, control serum of healthy probands (n = 38) with an average MT amount of 2.2 µg L–1, median 2.1 µg L–1 was used. In all evaluated blood serum samples of cancer patients (n = 228), the average amount of MT was 22.7 µg L–1, and the median was 18.1 µg L–1. The difference (10-fold) between groups was highly statistically significant. The data obtained from the pilot experiment suggest that the levels of thiol compounds such as MT may have clinical potential in cancer patients.

Published

2023-09-15

How to Cite

Melich, L., Fořtová, M., Hosnedlová, B., Podhájský, J., Rychlý, O., Werle, J., Burešová, K., Dunovská, K., Vysloužilová, L., Klapková, E., Kotaška, K., Čepová, J., Jedličková, B., Štěpánková, O., Průša, R., & Kizek, R. (2023). Study of Metallothionein Levels in the Serum of Patients with Malignant Tumour. Chemické Listy, 117(9), 573–580. https://doi.org/10.54779/chl20230573

Issue

Section

Articles

Most read articles by the same author(s)